Komori
Tms (4891) · InitiativeAdvanced

Securing Talent and Strengthening a Cross-Functional Organization

First written in FY2023. 2 of 4 entries say "Advanced", first in FY2024-Q1. Latest entry: FY2025.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2024-Q22023: 320232024: 020242025: 12025
Same theme, other companies
Expanding R&D Personnel and Strengthening the Development StructureA theme 51 companies write about · 0 as a headwind · 52 as a tailwind

The whole theme swung hardest in 2026: 3 of 34 companies on the "Worse" side.

31 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 51 companies compared. The sentences above are computed from all 51.
Full recordFilings, disclosures and news, newest first
  1. FY2025AdvancedAnnual report

    「The Company therefore recruited experienced personnel with track records in clinical development and business development.」

    The Company recruited experienced personnel with track records in clinical and business development, strengthening both functions.
  2. FY2024-Q2RestatedAnnual report

    「To promote the business through a stronger R&D structure, the Company changed its structure from 1 director overseeing all research and development to 2 directors overseeing research and development separately.」

    The Company continues to operate under a structure in which 2 directors separately oversee research and development following the change in April 2023.
  3. FY2024-Q1AdvancedAnnual report

    「The Company’s co-founder and Chairman, Keiji Hasumi, retired as a professor at Tokyo University of Agriculture and Technology upon reaching the mandatory retirement age on 31 March 2023 and became a full-time director of the Company on 1 April, taking the lead in research. Accordingly, to promote the business through a stronger R&D structure, the Company changed its structure from 1 director overseeing all research and development to 2 directors overseeing research and development separately.」

    The Company changed its structure from 1 director overseeing all R&D to 2 directors separately overseeing research and development. Keiji Hasumi’s appointment as a full-time director clarified responsibility for research.
  4. FY2023First statedAnnual report

    「Rather than organizing the Company into vertically divided specialist silos, it aims to create an organization in which personnel with expertise in research, manufacturing, regulatory affairs and development can engage freely in discussion, while actively recruiting talented personnel.」

    The Company aims to build a cross-functional organization where specialists in research, manufacturing, regulatory affairs and development can collaborate, while recruiting talented personnel.
Moved together

"Preclinical development and preparation for Phase I clinical trials of TMS-008" moved the same way as this thread, in the same document, in 2 of its 4 moves.

2★1
  1. ★This thread
  2. 1Preclinical development and preparation for Phase I clinical trials of TMS-0082×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Tms yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Securing Talent and Strengthening a Cross-Functional Organization | TMS Co.,Ltd. (4891) | Komori